**Talaromyces marneffei infection associated with bronchiolitis obliterans in an HIV-negative child: a case report**

Lin Lin, Huifeng Fan, Dongwei Zhang and Gen Lu*

**Abstract**

**Background:** *Talaromyces marneffei* is an opportunistic pathogen that infects immunodefficient and immunocompromised patients. We presented a pediatric patient with a diagnosis of *T. marneffei* infection who was followed up in the Guangzhou Women and Children's Medical Centre.

**Case presentation:** The child was a 5-year-old girl with persistent cough and gasping over 2 months who was confirmed with *T. marneffei* infection by bronchoalveolar lavage fluid culture and high-throughput sequencing technology. Human immunodeficiency virus (HIV) was negative according to a serum-specific antibody test. She was treated with amphotericin B and itraconazole as antifungal agents, with good clinical response. At follow-up, high-resolution computed tomography showed a mosaic sign in the whole lung field with a diagnosis of post-infectious bronchiolitis obliterans (PIBO) as the sequela. She has a mutated COPA gene with uncertain pathogenic potential on whole-exome sequencing.

**Conclusions:** Clinicians should consider PIBO as a possible sequela in an HIV-negative paediatric patient with *T. marneffei* infection.

**Keywords:** *Talaromyces marneffei*, Child, Sequelae, Bronchiolitis obliterans

**Background**

*Talaromyces marneffei* (formerly known as *Penicillium marneffei*) is an important dimorphic fungus. It is the only member in the genus that causes systemic mycosis and is more prevalent in South Asia [1]. In adults, *T. marneffei* infection has been considered to be exclusively associated with acquired immunodeficiency syndrome (AIDS) caused by human immunodeficiency virus (HIV) infection [2], although nowadays the infection rate in non-HIV-infected children has gradually grown [3], paediatric patients with primary immunodeficiency diseases (PIDs) being more susceptible according to previous reports [4, 5]. Here we report a rare case of post-infectious bronchiolitis obliterans (PIBO) as sequela after *T. marneffei* infection with a mutation in the *COPA* gene.

**Case presentation**

In January 2019, a 5-year-old girl was hospitalized with intermittent fever, cough and shortness of breath for two months and she had recurrent lower respiratory tract infection from infancy. There was no family history of PIDs and consanguineous marriage. On admission, she had difficulty breathing. Stridor and moist rales were revealed by auscultation. Rash, lymphadenopathy, and hepatosplenomegaly were all absent. HIV was negative according to a serum-specific antibody test and HIV viral load. Humoral immunoassay showed decreased serum immunoglobulin G (IgG), IgA and...
IgM, but the serum IgE level was normal. Lymphocyte counts were all in their normal range on admission, including CD4\(^+\) subsets, CD8\(^+\) subsets, natural killer (NK) cells and CD19\(^+\) subsets. The nitroblue tetrazolium test (NBT) was normal (Table 1).

High-resolution computed tomography (HRCT) showed small airway obstruction lesions, and bilateral diffuse infiltration and local bronchiectasis in both lungs (Fig. 1A–C). Electronic bronchoscopy showed heavy yellow-white purulent secretion in the airway, and bronchoalveolar lavage fluid (BALF) for culture yielded *T. marneffei* (Fig. 2). By the same token, high-throughput sequencing detected *T. marneffei* in BALF. In accordance with pathogenic status, amphotericin B deoxycholate at 20 mg/day was commenced as the primary antifungal therapy for 14 days with good clinical response, and the patient was discharged with oral itraconazole prescribed for 4 weeks.

One month after discharge, she presented to the emergency department with shortness of breath and oedema of eyelids and limbs. HRCT showed multiple patchy ground-glass opacities that manifested as mosaic attenuation (Fig. 3A–C). Culture of *T. marneffei* was negative in BALF and blood during this hospitalization. A restrictive abnormality with reduction of diffusion capacity was mainly found in pulmonary function. She was treated with intravenous Ig (400 mg/kg/day) for 3 days as well as aerosol inhalation of budesonide. After 10 days of treatment, the dyspnoea was relieved and she was discharged with recommended continued use of a Symbicort Turbuhaler.

### Follow-up and gene report

Cough and yellow phlegm were reduced, but intermittent wheezing symptoms still persisted after the patient left hospital. In addition, whole-exome sequencing identified a de novo missense mutation c.2437G > T(p.V813L) in the *COPA* gene (Fig. 4), but the mutation was predicted to be uncertain based on the American Center for Medical Genetics and Genomics guidelines. During the follow-up, the child still wheezed intermittently and did not show any positive symptoms of kidney or autoimmune inflammatory arthritis problems.

### Discussion and conclusion

*T. marneffei* is the only temperature-biphasic pathogenic fungus in *Penicillium*, and is endemic in Southeast Asia [6]. In adults, most *T. marneffei* infections occur in AIDS patients, especially HIV infected, while varying among children. We present the case of a child with sequelae of PBO arising from *T. marneffei* infection without HIV and accompanied by mutations in the *COPA* gene.

In many aspects, the clinical manifestations of paediatric patients with *T. marneffei* infection are not typical,

### Table 1 Laboratory findings of the patient on the day of admission

| Laboratory index | Result | Reference range |
|------------------|--------|-----------------|
| WBC (x 10^9/L)   | 18.6   | 5–12            |
| N (x 10^9/L)     | 13.02  | 2–7.2           |
| Hb (g/dL)        | 120.00 | 105–145         |
| PLT (x 10^9/L)   | 466.00 | 140–440         |
| CRP (mg/L)       | 11.21  | < 8.2           |
| IgG (g/L)        | 4.56   | 5.0–10.6        |
| IgA (g/L)        | 0.11   | 0.34–1.38       |
| IgM (g/L)        | 0.16   | 0.44–1.44       |
| IgE (IU/mL)      | 5.00   | 0–60.0          |
| CD3 +4+ (cells/µL) | 1223.43 | 345–2350       |
| CD3 +8+ (cells/µL)  | 382.35 | 314–2080       |
| CD19+ (cells/µL)  | 309.21 | 240–1317       |
| Th/Ts (%)        | 2.02   | 0.47–2.05       |
| NK (cells/µL)    | 285.62 | 210–1514        |

WBC white blood count, N neutrophils, Hb hemoglobins, PLT platelet count, CRP C-reactive protein, Th helper T cells, Ts inhibited T cells, NK natural killer

**Fig. 1** High-resolution computed tomography (CT) scan of the chest revealing small airway obstruction lesions with double pneumonia, insufficiency of the right middle and left lower lung segments, and local bronchiectasis in both lungs on first hospitalization
which is a potential reason for misdiagnosis of *T. marneffei* infection [7]. Our patient presented with fever, cough, and dyspnoea but there was no manifestation of disseminated *T. marneffei* infection, including rash, weight loss, lymphadenopathy, and hepatosplenomegaly in this patient as in the previous reports [8, 9]. Although the clinical history spanned 2 months, the diagnosis of *T. marneffei* infection was not confirmed until she was hospitalized in our centre. Positive culture and high-throughput sequencing of BALF were the most important criteria in the final diagnosis of *T. marneffei* infection in this child, suggesting that BALF can be used for the early diagnosis of such an infection.

PIDs that commonly manifest some degree of hypogammaglobulinemia include selective IgA deficiency, common variable immunodeficiency, and congenital agammaglobulinaemias. Less common causes include agammaglobulinaemia with thymoma (Good syndrome) and X-linked lymphoproliferative syndrome [10]. In addition, concomitant opportunistic infections in this child should raise suspicion of a cellular defect that also affects antibody production, such as nuclear factor κB essential modulator (NEMO; also called IKK-γ) or CD40 ligand (CD154) deficiencies [10, 11]. Because the exact kind of PIDs may be difficult to determine based on the peripheral immunological results alone, genetic testing was carried out. The patient was identified with a *de novo* missense mutation at exon 17 (c.2437G > T, p.V813L) in the *COPA* gene. Patients with *COPA* mutations typically have normal numbers and percentages of lymphocytes and lymphocyte subsets along with unremarkable Ig levels and intact production of specific antibodies [4, 12]. However, the child had markedly decreased Ig with normal numbers of lymphocytes. The exact mechanism by
which COPA gene mutation causes *T. marneffei* infection is currently unknown.

Pulmonary fungal infections complicated by PIBO sequelae are very rare. Recent research suggests that pulmonary colonization with *Aspergillus* species has been implicated as a potential risk factor in the development of PIBO [13]. However, *T. marneffei* infection with secondary PIBO had not been previously reported. According to her repeated dyspnoea and wheezing over a period of longer than 2 months and mosaic signs on HRCT, despite lung biopsy being essential for the diagnosis of PIBO this procedure was not performed in this patient because of her tender age, although PIBO was also considered in the differential diagnosis. Interestingly, lung involvement is usually in the form of interstitial lung disease in patients with COPA gene mutation [14] and, as such, the mechanism of PIBO might be a combination of *T. marneffei* infection and COPA gene mutation.

In conclusion, it must be stressed that while *T. marneffei* infection with PIBO is very rare, this patient also showed a de novo missense mutation in the COPA gene. Evidence from this report suggests that all clinicians must
consider PIBO as a possible sequela in an HIV-negative paediatric patient with *T. marneffei* infection. Moreover, the role of COPA in *T. marneffei* infection is worthy of further study.

Abbreviations
AIDS: Immunodeficiency syndrome; ACMG: American Center for Medical Genetics and Genomics; BALF: Bronchoalveolar lavage fluid; HIV: Human immunodeficiency virus; HRCT: High-resolution computed tomography; NBT: Nitroblue tetrazolium test; NK: Natural killer; PIBO: Post-infectious bronchiolitis obliterans; PID: Primary immunodeficiency disease.

Acknowledgements
We are very appreciative to the child and her families.

Authors’ contributions
L.L. and H.F.F. analyzed data and wrote the paper. L.L. and D.W.Z. collected patients’ clinical data and modified the paper. G.L. communicated with the parents and supervised the whole writing process. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
All data and materials of this article are included in the manuscript and are thus available to the reader.

Declarations

Ethics approval and consent to participate
This study protocol was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Guangzhou Women and Children’s Medical Centre of Guangzhou Medical University. Written informed consents were signed during hospitalization. The data used in this study were thus anonymised before its use.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests to disclose.

Received: 14 September 2021   Accepted: 18 April 2022
Published online: 16 May 2022

References
1. Ying RS, Le T, Cai WP, et al. Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011–2017. HIV Med. 2020;21(11):729–38. https://doi.org/10.1111/hiv.13024.
2. Vanittanakom N, Cooper CR, Fisher MC, Sirisanthana T. *Penicillium marneffei* pathogenicity and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev. 2006;19(1):95–110. https://doi.org/10.1128/CMR.19.1.95-110.2006.
3. Chi KH, Xue YM, Wang QS, et al. *Penicillium marneffei* Diagnosis and treatment of diffuse in human immunodeficiency virus-negative patients: a challenge for the physician. Indian J Med Microbiol. 2017;35(4):617–20. https://doi.org/10.4103/immm.IMM_15_418.
4. Qiang Zeng Y, Jin G, Yin, et al. Peripheral immune profile of children with *Talaromyces marneffei* infections: a retrospective analysis of 21 cases. BMC Infect Dis. 2021;21:287–94. doi:https://doi.org/10.1186/s12879-021-05978-z.
5. Pan M, Qu Y, Zeng W, et al. Disseminated *Talaromyces marneffei* infection presenting as multiple intestinal perforations and diffuse hepatic granulomatous inflammation in an infant with STAT3 mutation: a case report. BMC Infect Dis. 2020;20(1):394–400. https://doi.org/10.1186/s12879-020-05113-4.
6. Guo LN, Yu SY, Wang Y, et al. Species distribution and antifungal susceptibilities of clinical isolates of *Penicillium* and *Talaromyces* species in China. Int J Antimicrob Agents. 2021. https://doi.org/10.1016/j.ijantimicag.2021.106349.
7. Qiu Y, Lu DC, Zhang J, et al. Treatment of disseminated talaromyces marneffei with tracheal infection: two case reports. Mycopathologia. 2015;180(3–4):245–9. doi:https://doi.org/10.1007/s11046-015-9891-4.
8. Guo J, Li BK, Li TM, et al. Characteristics and prognosis of talaromyces marneffei infection in non-HIV-infected children in southern China. Mycopathologia. 2019;184(6):735–45. doi:https://doi.org/10.1007/s11046-019-00373-4.
9. Ding X, Huang H, Zhong L, et al. *Talaromyces marneffei* disseminated infection in a non-HIV infant with a homozygous private variant of Front Cell Infect Microbiol. 2021. https://doi.org/10.3389/fcimb.2021.605589.
10. Oliveira JB, Flesher TA. Laboratory evaluation of primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):297–305. https://doi.org/10.1016/j.jaci.2009.09.043.
11. Hanson EP, Monaco-Shawver L, Solt LA, Madge LA, Banerjee PP, May MJ, Orange JS. Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J Allergy Clin Immunol. 2008;122(5):1169–71716. doi:https://doi.org/10.1016/j.jaci.2008.08.018.
12. Stefano Volpi J, Tsui, Mariani M, et al. Type I interferon pathway activation in Copa syndrome. Clin Immunol 2018. doi:https://doi.org/10.1016/j.clim.2017.10.001.
13. Weigt SS, Copeland CAF, Derhovanessian A, et al. Colonization with small conidia Aspergillus species is associated with bronchiolitis obliterans syndrome: a two-center validation study. Am J Transplant. 2013;13:919–27. doi:https://doi.org/10.1111/ajt.12131.
14. Vece TJ, Watkin LB, Nicholas S, et al. Copa syndrome: a novel autosomal dominant immune dysregulatory disease. J Clin Immunol. 2016;36:377–87. doi:https://doi.org/10.1007/s10875-016-0271-8.